Paul Chaney
Founder bei PanOptica, Inc.
Profil
Paul G.
Chaney is the founder and currently holds the position of President, Chief Executive Officer & Director at PanOptica, Inc. which was founded in 2009.
He is also currently a Director at Lux Biosciences, Inc. and Ocugenix Corp.
In his former positions, Mr. Chaney served as Chairman at Oldtech, Inc. from 2008 to 2013.
He was also the Non-Executive Chairman at Kiora Pharmaceuticals, Inc. from 2022 to 2023.
Additionally, he held the role of Ophthalmology Director at The Upjohn Co. from 1995 to 1998.
Mr. Chaney was an Independent Director at Sesen Bio, Inc. from 2014 to 2018 and served as Executive Vice President at OSI Pharmaceuticals, Inc. from 2006 to 2008.
He also held the position of Chief Operating Officer at Eyetech, Inc. and was a Principal at Pharmacia Corp.
from 1998 to 2009.
Furthermore, he served as President at (OSI) Eyetech.
Mr. Chaney obtained his undergraduate degree from the University of Delaware.
Aktive Positionen von Paul Chaney
| Unternehmen | Position | Beginn |
|---|---|---|
Lux Biosciences, Inc.
 Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Director/Board Member | - |
PanOptica, Inc.
 PanOptica, Inc. Pharmaceuticals: MajorHealth Technology PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ. | Founder | 01.06.2010 |
Ocugenix Corp.
 Ocugenix Corp. Medical/Nursing ServicesHealth Services Ocugenix Corp. operates as a therapeutics company focusing on he development of of cancer immunotherapy drug for eye diseases. The company is headquartered in Pittsburgh, PA. | Director/Board Member | - |
Ehemalige bekannte Positionen von Paul Chaney
| Unternehmen | Position | Ende |
|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Chairman | 21.09.2023 |
| CARISMA THERAPEUTICS, INC. | Director/Board Member | 07.08.2018 |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Chairman | 13.12.2013 |
| OSI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.09.2008 |
| The Upjohn Co. | Corporate Officer/Principal | 01.01.1998 |
Ausbildung von Paul Chaney
| University of Delaware | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
| The Upjohn Co. | Health Technology |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Health Technology |
Eyetech, Inc.
 Eyetech, Inc. Medical SpecialtiesHealth Technology Eyetech Inc. is an independent employee-owned and operated biotechnology company dedicated exclusively to the treatment of sight-threatening diseases of the retina. Eyetech was established in August 2008 by an experienced and passionate group of former (OSI) Eyetech employees. Eyetech is headquartered in Palm Beach Gardens, Florida and operates virtually across the United States. Their leadership team includes nationally recognized leaders in ophthalmology and in the biotechnology industry. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
(OSI) Eyetech
 (OSI) Eyetech Medical SpecialtiesHealth Technology OSI Eyetech provides medical services. It is specializee in the development and commercialization of therapeutics to treat diseases of the eye. The company is headquartered in New York City, NY. | Health Technology |
PanOptica, Inc.
PanOptica, Inc. Pharmaceuticals: MajorHealth Technology PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Ocugenix Corp.
Ocugenix Corp. Medical/Nursing ServicesHealth Services Ocugenix Corp. operates as a therapeutics company focusing on he development of of cancer immunotherapy drug for eye diseases. The company is headquartered in Pittsburgh, PA. | Health Services |
